Portfolio Finder

IQ Evolution develops microcooling systems based on the selective laser melting technology for semiconductors used in high power diode lasers. This facilitates a significant increase in the lifetime of those components.

Itembase developed a web application that tracks more than 2,5 million purchases a month and that helps more than 15.000 web retailers increase their margins through using the full set of itembase e-commerce solutions.

JobLeads is the first quality controlled online recruiting channel allowing companies to systematically use the power of personal referrals to get cheaper and faster access to highly qualified candidates.

Founded in January 2014, Juniqe is a Berlin-based e-commerce site that specialises in art prints, apparel and accessories. Art lovers can discover new designs by independent artists every day.

Intelligent Job Search Engine, which searches job boards, recruiting agencies and company career sites for jobs. Artificial Intelligence helps identifying the best jobs.

Exit since Jan. 2015.

KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.

Exit since Feb. 2011. Purchaser: Evotec AG

kinkaa is a Meta Travel Search Engine for all relevant travel categories (flights, hotels, cars, packages and more to come) focusing on various European markets.

Exit since Sep. 2010.

Kiutra develops fully-automatic cooling solutions for the generation of extremely low temperatures near absolute zero at -273°C. In contrast to conventional Helium based cooling methods, kiutra’s magnetic cooling technique is user-friendly, requires low-maintenance and is scalable. It is therefore highly suitable e.g. for the cooling of quantum technologies at industrial scale.

Kiwigrid is an energy management system, which is connecting producers of renewable energy, consumers, storages, electric mobility and the energy grid with Microgrids.
Purchaser of HTGF-Shares: AQTON SE

Exit since December 2016.

Sample analysis in structural biology often suffers from weak contrast in the transmission electron microscope (TEM). The KonTEM PhazR solves this contrast problem and thus enables scientists to extract more information about structure and function of cells on molecular level.

Exit since May 2014. Purchaser: FEI Company (NASDAQ: FEIC)

Kõu Mobility Group consists of four micromobility companies: Comodule, which provides software and IoT solutions for light electric vehicles; Tuul, a rental service for electric scooters; Äike, a manufacturer of electric scooters; and Ampler, a developer of electric bicycles.

The group's vision is to encourage people to choose clean transportation and create a noise- and emission-free urban environment. The brands of Kõu Mobility Group make light electric vehicles safer, more comfortable and accessible.

Kranus Health aims to help men lead healthier and longer lives through access to the latest medical care. Founders Thilo Kleinschmidt and Jens Nörtershäuser have known each other for many years through their time together at McKinsey & Company, and both have been passionate about the possibilities of digital transformation for years. Both also had a keen interest in the health sector. Jens is originally a bio-chemical engineer and has years of professional experience in the pharmaceutical sector. Thilo comes from a medical family, his father is a urologist. So the idea to found Kranus at the beginning of 2020 was obvious and also took place against the backdrop of regulatory changes, especially the Digital Health Care Act (DVG). Since then, it has been possible in Germany to significantly improve healthcare through digital therapies. Professor Kurt Miller, former head physician of urology at Charité Berlin, and CTO Nikolay Dimolarov (Celonis, among others) complement the founding team to jointly implement Kranus' vision. To this end, Kranus Health develops digital therapies based on current scientific findings supported by telemedical care from specialists. The spectrum of services ranges from therapies for taboo diseases such as erectile dysfunction to early detection and prevention (e.g., cardiovascular diseases).

The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses on the processing of high-performance polymers, which are already established in medical technology. With the Kumovis system these plastics can be processed individually, decentrally and with a high degree of design freedom. Through the integration of a unique air circuit including filter units, the technology enables a clean room environment within the build chamber. The contamination of the component with foreign particles can be avoided. As a result, the Kumovis printer can produce products such as implants cost-effectively and at the same time patient-individualized.

Laclarée develops adaptive eyeglasses for presbyopia correction. Based on a patented technology, these eyeglasses offer presbyopes clear vision at all distances without levelling down aesthetic standards. Presbyopia appears by age 40-45 with increasing difficulties to focus at near distances and affects 400 million people in Europe, Japan and North America. Progressive lenses, featuring a vertical gradient of optical power, are today the best compromise to presbyopia correction. Still about 10% of presbyopes are very unsatisfied with these lenses, experiencing a reduced quality of life.
Laclarée’s product has been designed to answer this demand, corresponding to about 2 b€/y. Our solution relies on a disruptive fluid-filled doublet-lens activated by low-power microfluidic actuators inserted in the eyeglass arms and driven by a miniature infrared distance sensor. The lens offers a large field of view, is as transparent as any other ophthalmic lens and is compatible with most lens shapes and frame styles.
Laclarée’s team is highly motivated and gathers extensive skills in optics, microfluidic and vision science. The founder of Laclarée is an experienced entrepreneur, he has successfully established a world-leading company in variable optics for cameras. The team has achieved the Proof of Concept, with a fully functional portable demonstrator, enabling a small scale trial with presbyopic people and raising a marked interest in the ecosystem. Laclarée just closed its first seed investor round with Kreaxi and High-Tech Gründerfonds (HTGF).

LEON Mobility was founded in 2020 by two experts from the mobility industry who had clearly identified the problem of micro mobility: there is a lack of an economical and widespread charging infrastructure for sharing scooters. With XOO, LEON Mobility is building this smart charging infrastructure for sustainable micro mobility in public spaces. XOO charging points distributed across the city charge e-kick scooters and e-mopeds where the need is - efficiently, energy-saving and tidily. XOO is the game changer of micro-mobility. With XOO, mobility providers achieve considerable cost advantages, municipalities get a tidy cityscape and users get scooters ready to ride where they need them. Micro mobility is finally becoming a sustainable solution. For free roads, better air and tidy city centers.
XOO has already been able to achieve significant efficiency increases and improved sustainability for its customers with pilots. LEON Mobility is currently working on the roll-out for several urban customers and plans to grow significantly in 2022. At the same time, with the expansion of XOOnet, the individual XOO charging stations will be developed into AIoT Edge devices that will make XOOnet even smarter. With XOO, LEON Mobility will contribute to the successful implementation of the transport revolution and to the significant reduction of CO2 emissions in cities and municipalities.

LignoPure GmbH is a spin-off of the TU Hamburg that enables the valorization of Lignin, a byproduct of ethanol biorefineries and the pulp and paper industry, via a proprietary technology. The startup is pioneering in the use of lignin in care products and biobased high-performance materials. As key technology partner, LignoPure supports their customers in launching their own innovative and sustainable products by not only providing the tailored raw material but offering development services in the areas of material and life sciences.

Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood collected during the operation. The product consists of a combination of an antibody and filter and serves to remove cancer cells from the blood.

lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family offices. lino offers industry partners and researchers a unique way to study molecular interactions in living cells and crude biosystems.

Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.

Geotagging of fotos: Internet platform and clients for mobile devices.

LOEWI GmbH is a scientific spin-off of the TU München with the mission to make personalized health and nutrition available to everyone by combining science and technology. LOEWI's patented personalization concept analyzes health relevant data of customers and patients, makes the analysis available via LOEWI's Health Profile (Medical Software Class I), and creates personalized nutrient recommendations and therapies using a sophisticated recommendation algorithm, which are 100% tailored to the personal needs of each customer and patient.

Luphos develops and manufactures high-precision optical sensors for quality and process control in industrial fabrication as well as metrology platforms for the quality control of high precision optics.

Exit since May 2014. Purchaser: AMETEK Inc. (NASDAQ: Ametek)

Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting millions of people worldwide.
Lymphatica developed its implantable drainage technology as a results of years of research at the Lausanne Federal Institute of Technology (EPFL) and of the Lausanne University Hospital (CHUV).

m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated cultivation RoboLector® platforms, an integration of the BioLector® tool into a liquid handling system.
Proprietary online monitoring technology increases the number and the information content of microbial experiments, either aerobic, microaerophilic, or strictly anaerobic. Experiments can be conducted with excellent efficiency and high quality at low costs in microscale.

MAGAZINO develops, builds and sells innovative storage and picking machines. They enable highly efficient individual item storage and dispensing of a wide range of objects.

Exit since May 2015. Purchaser: Siemens Novel Businesses.

Makerist is the online destination for creative hobbies – to learn in a relaxed and success-oriented way with video classes, to find daily inspiration for your next project, to order all the material you need, and to connect with Europe’s biggest online hobby communities.

Materials Nexus is a deep tech company on a mission to discover next-generation materials for everyday items that don’t cost the earth. It uses AI to find sustainable, cheaper and higher-performance alternatives to the advanced materials which are used to build the technologies we understand to be vital for a net-zero world. Materials Nexus’ ground-breaking software can accurately predict the properties of sustainable materials and understand the costs and processes associated with scaling and manufacturing them – all in a matter of months, not decades.

Mbiomics is a Munich based microbiome startup company which was founded by Dr. Laura Figulla (CEO), Dr. Johannes Wöhrstein (CTO), and Dr. Markus Rinecker (CMO) in 2020. With its proprietary microbiome profiling technology at hand, mbiomics is uniquely positioned to understand microbiome modulation and to design effective microbiome therapies.

MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®.
Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases for which there are currently no satisfactory therapies and which lead to high mortality or poor quality of life. Examples include septic shock, acute GvHD and the lung disease BPD.
The mission of MDTB Cell Manufacturing GmbH is the industrial-pharmaceutical production of MSC-based drugs in Germany as clinically well manageable Advanced Therapy Medical Products (off-the-shelf/ready-to-use) to significantly improve the health of affected patients. The manufacturing costs and the progress made in scaling up should also enable application in large patient groups.
Desacell® is currently being tested internationally in several clinical studies.

Mecuris enables the individual and custom-made production of orthopaedic aids by means of an intuitive web-based platform and subsequent manufacturing using 3D printing. This includes orthoses (e.g. for stabilising the cervical spine) and prostheses (e.g. artificial limbs), as well as equipment such as covers for below-knee prostheses. Mecuris not only provides orthopaedic clinics and medical supply stores with its innovative platform, but also with a full service package right up to delivery of the manufactured products. Design data is adjusted to a patient’s anatomy in an automated fashion based on digital patient data (CT, scanning, photos).